The Garvan Institute of Medical Research (GIMR) is one of the largest independent medical research institutes in Australia, and forms part of the St Vincent’s Research Precinct in Darlinghurst, Sydney. The Institute was incorporated as an autonomous, non-profit research institute by the NSW Garvan Institute of Medical Research Act in 1984, and is academically affiliated with the UNSW Australia.
The Garvan Institute has over 500 research staff organised around six Research Divisions – Cancer, Diabetes & Obesity, Genomics and Epigenetics, Immunology, Neuroscience, and Bone Biology. Of particular relevance to ProMis is an ongoing collaboration between the Cancer, Immunology and Bone Biology Divisions in the area of bone metastasis. The Institute’s scientific activities are focussed on basic discovery-orientated research into molecular processes underpinning development and disease, and its translation into health applications.
The Garvan's research expertise includes genomics, epigenomics and bioinformatics, molecular and population genetics, molecular and cellular biology, immunology, physiology, endocrinology, biochemistry, and cell imaging. Emerging areas of strength, which reflect an evolution towards holistic and translational research activities, include major initiatives in clinical genomics, monoclonal antibody development, advanced molecular / cellular imaging technologies and systems biology.
A central theme of the institute’s research philosophy is the elucidation of the basic molecular events underlying human disease. Researchers at the Institute recognise the importance of overlapping involvement of different systems and processes in biological functions. This includes in areas such as cancer and bone homeostasis, and interactions between researchers in these disciplines are resulting in major breakthroughs in the understanding of both normal and disease processes in human biology.
It is the Garvan's vision that basic mechanistic discoveries underpin new insights into important biological problems, and that from this will flow a real understanding of the basis of human disease and development of new therapies that are more targeted and more specific than those currently available.